Nykode Therapeutics AS (OSL:NYKD)
kr 2.704 0.024 (0.9%) Market Cap: 882.98 Mil Enterprise Value: -446.23 Mil PE Ratio: 0 PB Ratio: 0.58 GF Score: 48/100

Nykode Therapeutics ASA Corporate Call Transcript

Dec 20, 2022 / 03:00PM GMT
Release Date Price: kr28.9 (-9.57%)
Operator

Greetings and welcome to the Nykode Therapeutics webcast. At this time, all participants are in a listen-only mode. A web question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.

I would now like to turn the call over to Chief Executive Officer, Michael Engsig. Thank you. You may begin.

Michael Engsig
Nykode Therapeutics ASA - CEO

Thank you very much. And again, a warm welcome to everybody. Good morning to the US. We are very, very excited to take you through our plans for the VB10.16 asset, which we have disclosed today.

And just a quick note on the forward-looking statements. We assume you are forward -- or familiar with these statements. On that note, we'll quickly move on.

With me today I have in the room, Agnete Fredriksen, our Co-Founder and Chief Business Officer; and Klaus Edvardsen, our Chief Development Officer. And Klaus will take you into a deeper dive on the on the VB10.16 development plans as well as the rationale of our plans.

But before handing over

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot